China biotech licensing deals 2026: the running list
A running repository of cross border licensing transactions, upfront commitments, and milestone structures from Chinese drug developers.
Snapshot
This reference page documents outbound cross border licensing agreements established by Chinese pharmaceutical and biotechnology developers for global market expansion, tracking contract structure, upfront funding, and total deal valuations. Designed for institutional healthcare investors and strategic corporate development teams, the sample reflects a structural shift toward global biopharma partnerships across oncology, ophthalmology, and platform technologies. Among major transactions, Eli Lilly committed $2.75B to collaborate with Insilico on AI developed drug candidates.
- Independent Research
What We Know
- Eli Lilly executed a deal with Insilico featuring an upfront payment of $115M to bring AI developed drugs globally. Additional payments remain tied to clinical and regulatory milestones for the artificial intelligence driven pipeline.
- Innovent Biologics entered a strategic global licensing agreement with Pfizer worth up to $10.5B to develop oncology medicines, causing Innovent shares to rise 10% following the announcement.
- RemeGen secured an upfront payment of RMB 250M alongside development and regulatory milestones up to RMB 520M and sales milestones up to RMB 525M. In addition, RemeGen is entitled to tiered royalties based on net sales of the product in the specified Greater China and Asian territories.
- Glenmark inked an $18M upfront deal with Hengrui for a cancer drug, backed by regulatory and commercial milestones up to $1.093B alongside additional sales royalties.
- Everest Medicines agreed to pay Vcare PharmaTech an upfront payment of RMB 20M under an exclusive agreement. The contract incorporates subsequent milestone payments and commercial supply procurement for the Asia Pacific region.
- Fosun Pharma subsidiary Fosun Pharma Industrial achieved overseas licensing for small molecule drug XH S004 for a potential total of $645M on August 11 2025.
- AstraZeneca licensed lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600M upfront plus potential milestones. The transaction secures rights for the lung cancer treatment to bolster the global oncology portfolio of the multinational buyer.
Octans View
Outbound transaction structures emphasize total valuation caps over immediate cash. Across the 7 deals recorded, front loaded capital commitments like the $600M upfront payment from AstraZeneca stand alongside large milestone packages such as the $1.093B expansion tied to Hengrui. Read together, these transactions describe one trend: global pharmaceutical majors are securing Chinese innovative drug assets through risk shared licensing frameworks to replenish aging pipelines.
Bear Case · Room for Disagreement
List boundaries exclude unannounced pipeline transactions, with the largest transaction recorded being the $10.5B deal between Innovent Biologics and Pfizer. Across the sample reported by 5 publishers, including 2 denominated in non USD currency, the smallest USD deal recorded is the $18M upfront agreement between Glenmark and Hengrui, demonstrating that headline valuations frequently include milestones that may never be fully realized if clinical targets are missed.
Sources
- [1]benzinga.com — Eli Lilly Strikes $2.75B Deal To Bring AI-Developed Drugs Globally. Eli Lilly's deal involves an upfront payment of $115 million to Insilico, with additional payments tied to milestones.
- [2]cnbc.com — Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion. Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.
- [3]manilatimes.net — RemeGen will receive upfront payment of RMB 250 million, development and regulatory milestone payments of up to RMB 520 million, and sales milestone payments of up to RMB 525 million. In addition, RemeGen will be entitled to tiered royalties based on net sales of the product in t
- [4]livemint.com — Glenmark inks $18 million deal for cancer drug with China’s Hengrui. The deal involves an upfront payment of $18 million, followed by regulatory and commercial milestone payments of up to $1.093 billion, as well as royalties.
- [5]manilatimes.net — Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.
- [6]manilatimes.net — Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million. SHANGHAI, Aug. 12, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a
- [7]thehindubusinessline.com — AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.
Every figure above traces to a listed source, and no report publishes without at least three independent publishers. How we verify. Found an error? Tell us and we correct it in public.
$115M